Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 3 of 382 rows for Tau propagation mechanism (preclinical target rationale). One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Tau propagation mechanism (preclinical target rationale) Medicines | Treatment |
No direction reported
whyA mechanism study: it shows Arc packages tau into extracellular vesicles and that cell-to-cell tau transmission is almost absent in Arc knockout mice, with Arc levels correlating with phosphorylated tau in human AD brain vesicles. It tests no intervention and estimates no effect on an outcome. |
Tau content and seeding potential of brain extracellular vesicles, and intercellular tau transmission, in tau-transgenic mice lacking Arc | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Cell
2026 ✓ Peer-reviewed PMID 42372723 |
| Tau propagation mechanism (preclinical target rationale) Medicines | Treatment |
Harm
whyDirection is for tau seeding activity: substantial hippocampal and neocortical seeding was present even without overt neocortical tangles and predicted region-specific cognitive performance and longitudinal decline; seeding and modification profiles tracked neuritic plaque density and separated AD from PART. |
Tau seeding activity and post-translational modifications in hippocampus and neocortex of Braak-matched AD neuropathologic change versus primary age-related tauopathy, and relation to cognition | None | 38 | not established — pubmed abstract reports no numeric effect size. |
Nature Communications
2025 ✓ Peer-reviewed PMID 39984462 |
| Tau propagation mechanism (preclinical target rationale) Medicines | Treatment |
No direction reported
whyA model-building and screening study: it identifies over 500 genetic modifiers of tau propagation (including VPS29 and the UFMylation cascade) and shows UFMylation inhibition suppresses seeded propagation in vitro and in vivo. It estimates no effect on a clinical outcome. |
Seeding-induced tau propagation in human iPSC-derived 4R-P301S neurons, and genetic modifiers found by CRISPRi screen | None | not stated | not established — pubmed abstract reports no numeric effect size. |
Cell
2024 ✓ Peer-reviewed PMID 38582079 |
Last updated